The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | Zanidatamab + chemo as 1L therapy in HER2-expressing GEA
Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents an update on a Phase II study evaluating zanidatamb and chemotherapy in the first-line (1L) treatment of patients with HER2-expressing gastroesophageal adenocarcinoma (GEA). In this ongoing study, zanidatamab with standard 1L chemotherapy shows an encouraging confirmed objective response rate and response durability in patients with HER2+ gastroesophageal adenocarcinoma with a manageable safety profile. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
